1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea.

Tbe FDA approved retifanlimab-dlwr (Zynyz; Incyte), a PD-1-targeting mAb, in combination with chemotherapy for patients with inoperable or metastatic squamous cell carcinoma of the anal canal (SCAC).

Major Finding: Brain metastases that arise from various primary sites characteristically harbor chromosomal instability and an immunosuppressive stromal/immune composition.

1Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, ...

Researchers at the American Association for Cancer Research Annual Meeting 2025 demonstrated that a bridged proteolysis targeting chimera (PROTAC) could enable the inclusion of more ligases in the ...

The FDA granted accelerated approval to the antibody–drug conjugate (ADC) telisotuzumab vedotin (Emrelis; AbbVie), which targets the receptor tyrosine kinase c-Met, for patients with locally advanced ...

The FDA has approved belzutifan (Welireg; Merck) for patients with locally advanced, inoperable, or metastatic pheochromocytoma or paraganglioma (together known as PPGL), rare neuroendocrine tumors ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

1Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute, Seattle, Washington.

1Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2Department of Health Sciences, Boston University, Boston, Massachusetts.

1Department of Radiation Oncology, Stanford University, Stanford, California. 2Stanford Cancer Institute, Stanford University, Stanford, California.

1Cancer Metastasis Laboratory, University College London Cancer Institute, London, United Kingdom. 2Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, United Kingdom.